The decrease in nonsplenic interleukin-6 (IL-6) production after splenectomy indicates the existence of a positive feedback loop of IL-6 production during endotoxemia in dogs

The spleen is involved in endotoxin-induced interleukin-6 (IL-6) production. To quantitate the relative contribution of the spleen to endotoxin-induced IL-6 production, we studied the effect of endotoxin (1.0 microg/kg of body weight) in control dogs (n = 7) and splenectomized dogs (n = 7). Blood for analysis of tumor necrosis factor (TNF) and IL-6 was sampled from the femoral artery and the portal, hepatic, and splenic (only in controls) veins. Arterial plasma endotoxin and cortisol levels were also measured. Whole-body IL-6 production was calculated by a deconvolution technique. Splenic IL-6 production in control dogs was measured from splenic blood flow and arteriovenous concentration differences. Endotoxin levels were higher in splenectomized dogs (P < 0.05) because of a decreased distribution volume (P < 0.05) and decreased clearance of endotoxin (P < 0.05). Endotoxin-induced plasma IL-6 levels were decreased by approximately 75% in splenectomized dogs (P < 0.01), and whole-body IL-6 production rates were severalfold lower (median of 8.7 mg/4 h and range of 3.9 to 11.4 mg/4 h versus a median of 32.3 mg/4 h and a range of 22.7 to 70.2 mg/4 h) (P < 0.05). However, in control dogs splenic IL-6 production (0.6 +/- 0.2 mg/4 h) was only approximately 2% of whole-body IL-6 production. Plasma TNF levels increased in both groups (P < 0.01) but were not different between the groups. Plasma cortisol levels were slightly higher in splenectomized dogs than in control dogs (P < 0.05). In conclusion, splenectomy decreases the distribution volume and clearance rate of endotoxin. Splenectomy results in decreased endotoxin-induced IL-6 production, which is caused not by the absence of splenic IL-6 production, but by a decrease in nonsplenic IL-6 production. Therefore, the spleen is an important mediator in the complete activation of nonsplenic IL-6 production by endotoxin.

[1]  L. Aarden,et al.  Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. , 1996, The Journal of clinical investigation.

[2]  G. Fantuzzi,et al.  Defective inflammatory response in interleukin 6-deficient mice , 1994, The Journal of experimental medicine.

[3]  D. Murasko,et al.  Monocyte culture and adherence modifies LPS-induced IL-6 production and inhibition by hydrocortisone. , 1994, Clinical immunology and immunopathology.

[4]  T. Jones.  Interleukin‐6 an endocrine cytokine , 1994, Clinical endocrinology.

[5]  A. Ogata,et al.  Systemic production of interleukin-6 following acute inflammation. , 1993, Biochemical and biophysical research communications.

[6]  J. H. Johnson,et al.  The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. , 1992, The Journal of clinical investigation.

[7]  J. Ali,et al.  Pneumatic antishock garment decreases hemorrhage and mortality from splenic injury. , 1991, Canadian journal of surgery. Journal canadien de chirurgie.

[8]  Z. Ba,et al.  The Complex Pattern of Cytokines in Sepsis Association Between Prostaglandins, Cachectin, and Interleukins , 1991, Annals of surgery.

[9]  T. J. Hayes,et al.  Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. , 1991, The American journal of physiology.

[10]  D. Remick,et al.  Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. , 1991, Journal of immunology.

[11]  D. Remick,et al.  Endotoxin-induced cytokine gene expression in vivo. II. Regulation of tumor necrosis factor and interleukin-1 alpha/beta expression and suppression. , 1990, The American journal of pathology.

[12]  S. Moestrup,et al.  Cellular targets and receptors for interleukin‐6 II. Characterization of IL‐6 binding and receptors in peripheral blood cells and macrophages , 1990, European journal of clinical investigation.

[13]  C. Petersen,et al.  Cellular targets and receptors for interleukin‐6 I. In vivo and in vitro uptake of IL‐6 in liver and hepatocytes , 1990, European journal of clinical investigation.

[14]  M. Kluger,et al.  Plasma profiles of IL-6 and TNF with fever-inducing doses of lipopolysaccharide in dogs. , 1990, The American journal of physiology.

[15]  A C Allison,et al.  The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. , 1990, The Journal of clinical investigation.

[16]  J. Vilček,et al.  IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. , 1989, Journal of immunology.

[17]  A. Waage,et al.  Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo , 1989 .

[18]  S. Rosenberg,et al.  In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice. , 1989, Journal of immunology.

[19]  W. Fiers,et al.  Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma , 1989, The Journal of experimental medicine.

[20]  L. Moldawer,et al.  Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. , 1989, Journal of immunology.

[21]  W. Fiers,et al.  Genes for IFN-beta-2 (IL-6), tumor necrosis factor, and IL-1 are expressed at high levels in the organs of normal individuals. , 1988, Journal of immunology.

[22]  L. Aarden,et al.  Functional discrimination between interleukin 6 and interleukin 1 , 1988, European journal of immunology.

[23]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[24]  M. Nishioka,et al.  Fate of 3H-labeled endotoxin in partially hepatectomised rats. , 1988, Hepato-gastroenterology.

[25]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[26]  C. Galanos,et al.  Distribution and localization of endotoxin in the reticulo-endothelial system (RES) and in the main vessels of the rat during shock. , 1985, Pathology, research and practice.

[27]  M. Entman,et al.  Comparison of hepatic extraction of insulin and glucagon in conscious and anesthetized dogs. , 1983, Endocrinology.

[28]  E. Wisse,et al.  Uptake by liver cells of endotoxin following its intravenous injection. , 1981, Laboratory investigation; a journal of technical methods and pathology.

[29]  R. Ulevitch,et al.  The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. , 1979, Journal of immunology.

[30]  G. Bottoms,et al.  Plasma concentrations of endotoxin following jugular or portal injections of endotoxin and following gastrointestinal ischemia due to hemorrhage. , 1991, Circulatory shock.

[31]  J. Vincent,et al.  Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. , 1991, Cytokine.

[32]  L A Aarden,et al.  Increased plasma levels of interleukin-6 in sepsis. , 1989, Blood.

[33]  J. T. ten Cate,et al.  Endotoxin testing in blood. , 1987, Progress in clinical and biological research.

[34]  Jack Levin,et al.  Detection of bacterial endotoxins with the Limulus amebocyte test : proceedings of an international conference held in Woods Hole, Massachusetts, September 8-11, 1985 , 1987 .

[35]  Detection of bacterial endotoxins with the Limulus amebocyte lysate test. Proceedings of an international congress. Woods Hole, Massachusetts, September 8-11, 1985. , 1987, Progress in clinical and biological research.